Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.32 (market cap $4.59B), while Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.7× Definium Therapeutics Inc. Common Shares's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Halozyme Therapeutics Inc. Common Stock for 0 Days on average.
| DFTX | HALO | |
|---|---|---|
Market Cap | $4.59B | $12.58B |
Volume | 2,103,937 | 2,179,278 |
Sector | Health | Health |
52-Week High | $48.45 | $115.22 |
52-Week Low | $10.68 | $61.63 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.55B | $14.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
